STCube

STCube EBIT Margin

The EBIT Margin (Operating Margin) of STCube (052020.KQ) as of Oct 24, 2026 is -336.09 %. In the previous year, EBIT Margin (Operating Margin) was -200.18 % — a change of 67.89% (lower).

EBIT Margin

-336.09 %

YoY

67.89%

Last updated:

EBIT Margin (Operating Margin) of STCube is 2025 -336.09 % . EBIT Margin (Operating Margin) of STCube was 2024 -200.18 % . It decreases by 67.89% lower compared to the previous year.

STCube's operating (EBIT) margin stands at -336.1%, down from -239.1% several years earlier.

The STCube EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-102.94 KRW
Jan 1, 2019
-55.68 KRW
Jan 1, 2020
-124.19 KRW
Jan 1, 2021
-239.09 KRW
Jan 1, 2022
-300.80 KRW
Jan 1, 2023
-446.89 KRW
Jan 1, 2024
-200.18 KRW
Jan 1, 2025
-336.09 KRW
The STCube EBIT Margin history
YEAREBIT MarginYoY
-336.09 %+67.89%
-200.18 %-55.21%
-446.89 %+48.57%
-300.80 %+25.81%
-239.09 %+92.51%
-124.19 %+123.05%
-55.68 %-45.91%
-102.94 %-39.25%
-169.45 %+1,005.69%
-15.33 %-83.65%
-93.71 %+561,155.79%
-0.02 %-96.74%
-0.51 %-2,462.64%
0.02 %-42.45%
0.04 %-167.93%
-0.06 %-58.98%
-0.14 %+140.21%
-0.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

EBIT Margin (Operating Margin) of STCube is -336.09 % in 2025.

EBIT Margin (Operating Margin) of STCube changed from -200.18 % to -336.09 %, representing a 67.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) STCube since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — STCube

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — STCube